Victory Capital Management
URGN icon

Victory Capital Management’s UroGen Pharma URGN Stock Holding History

Victory Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-61,050
Closed -$1.09M – 3258
2020
Q1 		$1.09M Buy
61,050
+26,584
+77% +$718K ﹤0.01% 1820
2019
Q4 		$1.15M Buy
34,466
+1,451
+4% +$39.6K ﹤0.01% 1703
2019
Q3 		$787K Buy
33,015
+32,162
+3,770% +$1.05M ﹤0.01% 1751
2019
Q2 		$31K Hold
853
– – ﹤0.01% 1776
2019
Q1 		$32K Hold
853
– – ﹤0.01% 1730
2018
Q4 		$37K Sell
853
-162
-16% -$7.28K ﹤0.01% 1713
2018
Q3 		$48K Buy
+1,015
New +$47.2K ﹤0.01% 1728

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Victory Capital Management's URGN Position: Q2 2020 in Review

Victory Capital Management sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 61,050 shares — an estimated $1.09M sold.

Victory Capital Management first reported a position in URGN in Q3 2018 and held it in 7 quarters. The position peaked at $1.15M in Q4 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

  • Victory Capital Management reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 61,050 UroGen Pharma shares in Q2 2020, an estimated $1.09M.
  • Victory Capital Management first reported a position in UroGen Pharma in Q3 2018 and held it in 7 quarters.
  • Victory Capital Management's UroGen Pharma position peaked at $1.15M in Q4 2019.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.